Advaxis, Inc. (ADXS)
Chart Events
Performance Outlook
| Previous Close | 0.1175 |
| Open | 0.1130 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 900 |
| Day's Range | 0.1040 - 0.1640 |
| 52 Week Range | 0.1040 - 1.5700 |
| Volume | |
| Avg. Volume | 3,374,806 |
| Market Cap | 21.409M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1710 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company entered into an agreement with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold will have an aggregate stated value of $5,000,000. Each share of the Series D pre
- GlobeNewswire
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease progression Preliminary data show disease control rate of 67% in first 3 patients in Part C, with ADXS-503 being dosed in combination with pembrolizumab in first line MONMOUTH JUNCTION, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the de
- PR Newswire
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. Advaxis, Inc. previously traded on NASDAQ.
